

31 August 2011

## TENDER RESULTS

The PHARMAC Board (or Chief Executive under Delegated Authority) has resolved to award tenders for Sole Subsidised Supply Status and Hospital Supply Status for some products included in the 2010/11 Invitation to Tender, dated 2 November 2010 and 2009/10 Invitation to Tender, dated 4 December 2009.

As discussed in our 2010 tender consultation document, we are notifying tender decisions as they are made in 2011. This change is to provide maximum notification of upcoming changes to the market, specifically to incumbent suppliers.

Some of the pharmaceuticals that will be delisted when the period of Sole Subsidised Supply commences may be subject to existing listing contracts with PHARMAC. Suppliers of pharmaceuticals that are subject to such contracts should continue to supply their pharmaceuticals under those contracts. PHARMAC will continue to subsidise those pharmaceuticals accordingly until such time as those pharmaceuticals are delisted.

### Notification of Product Changes (NOPC) forms and Pharmacodes

Please note that for any changes (price change, pack size change, new listing etc) to be effective in the Pharmaceutical Schedule (including Section H), suppliers are required to notify any changes to PHARMAC and the Pharmacy Guild of New Zealand by 4pm on the **12<sup>th</sup> of the month prior to the date of subsidy change**. More information and NOPC forms can be found on our website – [www.pharmac.govt.nz/schedule.asp](http://www.pharmac.govt.nz/schedule.asp).

Where a product does not have a current pharmacode, suppliers are required to ensure a pharmacode has been received from the Pharmacy Guild of New Zealand before the 12<sup>th</sup> of the month prior to the date of listing. PHARMAC cannot list a product (and pharmacies cannot claim) without the correct pharmacode.

---

**Note: This tender notification has been amended as Temozolomide was included in the 2009/10 Tender and therefore has Supply Status and Hospital Supply Status until 30 June 2013, not 30 June 2014.**

---

**2010/11 Tender – Sole Subsidised Supply Status or Hospital Supply Status applies until 30 June 2014**

**Community pharmaceutical tenders – Section B of the Pharmaceutical Schedule**

1. Tenders awarded to pharmaceuticals where at least one other brand is listed.

The decisions were as follows:

Chemical Name	Presentation; Pack size and type	Current subsidy and price	New subsidy and price	Sole supply brand (Supplier)	Date of listing/subsidy change for tender winning brand	Date of reference pricing of other listed brands	Sole Subsidised Supply date (and delisting of other listed brands)	Brand (Supplier) affected by reference pricing and delisting
Cefazolin sodium	Inj 500 mg; 5 vials	\$5.00	\$3.99	AFT (AFT)	1 January 2012	1 March 2012	1 June 2012	Hospira (Hospira)
Cefazolin sodium	Inj 1 g; 5 vials	\$8.00	\$3.99	AFT (AFT)	1 January 2012	1 March 2012	1 June 2012	Hospira (Hospira)

**Hospital pharmaceutical tenders – Section H of the Pharmaceutical Schedule**

2. Tenders awarded to pharmaceuticals where no brand is listed.

The decisions were as follows:

Chemical Name	Presentation; Pack size and type	Pack price	Hospital Supply Brand (Supplier)	DV Limit	Listing date	Hospital Supply Status date
Fentanyl	10 µg per ml, 50 ml; 10 prefilled syringes	\$165.00	Biomed (Biomed)	1%	1 October 2011	1 December 2011
Fentanyl	20 µg per ml, 50 ml; 10 prefilled syringes	\$185.00	Biomed (Biomed)	1%	1 October 2011	1 December 2011
Fentanyl	10 µg per ml, 50 ml; 10 premixed bags	\$210.00	Biomed (Biomed)	1%	1 October 2011	1 December 2011
Fentanyl	10 µg per ml, 100 ml; 10 premixed bags	\$210.00	Biomed (Biomed)	1%	1 October 2011	1 December 2011
Morphine sulphate	Inf 1 mg per ml, 100 ml; 10 premixed bags	\$165.00	Biomed (Biomed)	1%	1 October 2011	1 December 2011

3. Tenders awarded to listed pharmaceuticals where only the current brand is listed.

The decisions were as follows:

Chemical Name	Presentation; Pack size and type	Current pack price	New pack price	Hospital Supply Brand (Supplier)	DV Limit	Date of price change	Hospital Supply Status date
Morphine sulphate	Inj 1 mg per ml, 10 ml; 10 prefilled syringes	\$34.50	\$39.50	Biomed (Biomed)	1%	1 October 2011	1 December 2011
Morphine sulphate	Inj 1 mg per ml, 50 ml; 10 prefilled syringes	\$59.50	\$79.50	Biomed (Biomed)	1%	1 October 2011	1 December 2011
Morphine sulphate	Inj 2 mg per ml, 30 ml; 10 prefilled syringes	\$95.00	\$135.00	Biomed (Biomed)	1%	1 October 2011	1 December 2011

4. Tenders awarded to listed pharmaceuticals where at least one other brand is listed.

The decisions were as follows:

Chemical Name	Presentation; Pack size and type	Current pack price	New pack price	Hospital Supply Brand (Supplier)	DV Limit	Date of listing/price change for tender winning brand	Hospital Supply Status date (and delisting of other listed brands)	Brand (Supplier) to be delisted
Cefazolin sodium	Inj 500 mg; 5 vials	\$5.00	\$3.99	AFT (AFT)	1%	1 January 2012	1 March 2012	Hospira (Hospira)
Cefazolin sodium	Inj 1 g; 5 vials	\$8.00	\$3.99	AFT (AFT)	1%	1 January 2012	1 March 2012	Hospira (Hospira)

**2009/10 Tender – Sole Subsidised Supply Status or Hospital Supply Status applies until 30 June 2013**

**Community pharmaceutical tenders – Section B of the Pharmaceutical Schedule**

5. Tenders awarded to pharmaceuticals where at least one other brand is listed.

The decisions were as follows:

Chemical Name	Presentation; Pack size and type	Current subsidy and price	New subsidy and price	Sole supply brand (Supplier)	Date of listing/subsidy change for tender winning brand	Date of reference pricing of other listed brands	Sole Subsidised Supply date (and delisting of other listed brands)	Brand (Supplier) affected by reference pricing and delisting
Temozolomide	Cap 5 mg; 5 capsules, bottle	\$50.00	\$16.00	Temacoord (Douglas)	1 January 2012	1 March 2012	1 June 2012	Temodal (MSD)
Temozolomide	Cap 20 mg; 5 capsules, bottle	\$170.00	\$72.00	Temacoord (Douglas)	1 January 2012	1 March 2012	1 June 2012	Temodal (MSD)
Temozolomide	Cap 100 mg; 5 capsules, bottle	\$840.00	\$350.00	Temacoord (Douglas)	1 January 2012	1 March 2012	1 June 2012	Temodal (MSD)
Temozolomide	Cap 250 mg; 5 capsules, bottle	\$2,100.00	\$820.00	Temacoord (Douglas)	1 January 2012	1 March 2012	1 June 2012	Temodal (MSD)

**Hospital pharmaceutical tenders – Section H of the Pharmaceutical Schedule**

6. Tenders awarded to listed pharmaceuticals where at least one other brand is listed.

The decisions were as follows:

Chemical Name	Presentation; Pack size and type	Current pack price	New pack price	Hospital Supply Brand (Supplier)	DV Limit	Date of listing/price change for tender winning brand	Hospital Supply Status date (and delisting of other listed brands)	Brand (Supplier) to be delisted
Temozolomide	Cap 5 mg; 5 capsules, bottle	\$50.00	\$16.00	Temacoord (Douglas)	1%	1 January 2012	1 March 2012	Temodal (MSD)
Temozolomide	Cap 20 mg; 5 capsules, bottle	\$170.00	\$72.00	Temacoord (Douglas)	1%	1 January 2012	1 March 2012	Temodal (MSD)
Temozolomide	Cap 100 mg; 5 capsules, bottle	\$840.00	\$350.00	Temacoord (Douglas)	1%	1 January 2012	1 March 2012	Temodal (MSD)
Temozolomide	Cap 250 mg; 5 capsules, bottle	\$2,100.00	\$820.00	Temacoord (Douglas)	1%	1 January 2012	1 March 2012	Temodal (MSD)

## Tender declines - Products where no tender is to be awarded for Sole Subsidised Supply Status or Hospital Supply Status

The PHARMAC Board (or Chief Executive under Delegated Authority) resolved not to award tenders for Sole Subsidised Supply Status or Hospital Supply Status for the following products listed in the 2010/11 Invitation to Tender, dated 2 November 2010:

Chemical Name	Line Item	Chemical Name	Line Item
Morphine sulphate	Inj 1 mg per ml, 30 ml prefilled syringe	Beclomethasone dipropionate	Metered aqueous nasal spray, 50 µg per dose
Budesonide	Metered aqueous nasal spray, 50 µg per dose	Beclomethasone dipropionate	Metered aqueous nasal spray, 100 µg per dose
Budesonide	Metered aqueous nasal spray, 100 µg per dose	Iron sucrose	Inj 20 mg per ml

The PHARMAC Board (or Chief Executive under Delegated Authority) resolved not to award tenders for Sole Subsidised Supply Status or Hospital Supply Status for the following products listed in the 2009/10 Invitation To Tender, dated 4 December 2009:

Chemical Name	Line Item	Chemical Name	Line Item
Levonorgestrel	Tab 750 µg – 1.5 mg		

For products included in the 2009/10 Invitation to Tender and 2010/11 Invitation to Tender where no announcement has yet been made, either a decision is still pending or is provisional, subject to the product gaining market approval and being available to supply, and subject to PHARMAC Board (or Chief Executive) approval. We will keep you informed of any updates regarding such tender products as decisions are made.

If you have any queries regarding this notification please contact PHARMAC on 0800 66 00 50.